Adrenomedullin (AM) is a potent hypotensive peptide. Plasma contains mature-type AM (m-AM), which is amidated at the carboxy terminus, and an intermediate, AM-Gly. We developed a one-step two-site IRMA specific for determining human m-AM with monoclonal antibodies. The detection limit was 0.5 pmol/L, and the working range (CV <15%) was 1-300 pmol/L. Dilution of plasma samples showed good linearity. The recovery of added AM was 91-118%. The intra-and interassay imprecision values (CVs) were 4.4 -8.2% and 5.5-8.3%, respectively. The assay had no cross-reactivity with AM-Gly or other peptides similar to AM. The mean (؎ SD) plasma human m-AM concentration of 61 healthy subjects was 1.18 ؎ 0.65 pmol/L. In conclusion, our IRMA makes it possible to specifically measure m-AM, using a small amount of plasma sample (0.2 mL) by a one-step overnight assay without prior extraction. Our simplified method would be suitable for clinical studies on AM, especially when large numbers of samples must be processed.
Adrenomedullin (AM) 4 was discovered in pheochromocytoma tissue by monitoring increases in platelet cAMP activity (1) . The peptide, which consists of 52 amino acids, has one intramolecular disulfide bond and an amidated C terminus. AM also shows a slight homology with calcitonin gene-related peptide (CGRP) and amylin, which also have a six-amino acid ring structure and an amidated C terminus (1) . AM elicited a potent and long-lasting hypotensive effect mainly by vasodilation when injected intravenously into anesthetized rats (1, 2) . Sequence analysis of human AM cDNA showed that the precursor protein is 185 amino acids in length and includes the putative signal peptide (3) .
Development of the RIA revealed that a considerable amount of AM was present in several types of nondiseased human tissues, among which it was especially abundant in the adrenal medulla, lungs, kidneys, and cardiac atrium and ventricle (4) . Cultured endothelial cells and vascular smooth muscle cells actively produced AM, and the AM gene was also expressed in intact rat aorta (5, 6) . In addition, it was reported that AM circulates in the blood (7) , and its concentration was increased in patients with essential hypertension (7), heart failure (8, 9) , renal failure (10) , and sepsis (11) when compared with healthy subjects. It was conjectured that AM is synthesized as AM-Gly, which is an intermediate that has a glycine residue attached to the C terminus, and that the C terminus is amidated enzymatically for conversion into a biologically active form, hereafter called "mature-type" AM (m-AM) (3, 12) . Recently, m-AM and AM-Gly have been reported to be present in plasma (12) . However, competitive RIAs, which were used in previous studies, cannot distinguish between m-AM and AM-Gly, include an extraction step, which is tedious and time-consuming, and require as much as 1-5 mL of plasma sample (7) (8) (9) (10) (11) (12) (13) (14) .
Here, we describe the establishment of a simple onestep two-site IRMA specific for m-AM, with two kinds of monoclonal antibodies, and the development of an assay kit, which does not require extraction and which is rapid and precise enough for routine determination of m-AM in human plasma.
Materials and Methods reagents
AM, pro-AM N-terminal 20 peptide, and peptide hormones similar to AM, such as CGRP, amylin, calcitonin, and neuropeptide Y, were purchased from Peptide Insti-tute, Inc. Rabbit anti-biotin serum was purchased from Rockland, Inc.
peptide synthesis
Human AM fragments AM (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , AM(46-52)NH 2 , AM(46-52), AM(38-52), and AM(30-41) were synthesized using a solid phase method with a peptide synthesizer (431A; Applied Biosystems) and using 4-hydroxymethylphenoxymethyl-copolystyrene-1% divinylbenzene resin as a starting material according to the strategy using 9-fluorenylmethoxycarbonyl. All coupling reactions were carried out by the dicyclohexylcarbodiimide-1-hydroxybenzotriazole method, with 1-methyl-2-pyrrolidone as the solvent. After the chain elongation was completed, the protected peptide resins (1.06 -1.28 g) were cleaved with a mixture containing 10 mL of trifluoroacetic acid (TFA), 750 mg of phenol, 500 L of thioanisole, 500 L of H 2 O, and 250 L of 1,2-ethanedithiol for 3.5-13 h at room temperature. The crude products were extracted by washing with TFA. After the volatile materials were removed under reduced pressure, ethyl acetate was added to the crude residue. The resulting precipitate was washed with ethyl acetate to remove trace amounts of scavengers. For disulfide bond formation of AM (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , the peptide was first reduced with dithiothreitol; the disulfide bridge was then formed by means of air oxidation, with the conditions set for a sample concentration of 0.5 g/L in 0.1 mol/L NH 4 OAc solution (pH 8.1) for 18 h at room temperature. The crude peptides were purified by reversed-phase HPLC on a YMC-GEL ODS-AM 120-S50 column (4 ϫ 25 cm) with a mixture of H 2 O and acetonitrile as solvent (containing 1 mL/L TFA) systems at a flow rate of 1 mL/min. The concentrations of acetonitrile on purification of AM (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , AM(46-52), AM(46-52), AM(38-52) and AM(30-41) by reversed-phase HPLC were 180, 120, 140, 180, and 170 mL/L, respectively. The amino acid composition of the synthetic peptides was determined by amino acid analysis with an Hitachi L-8500 amino acid analyzer after hydrolysis in 6 mol/L HCl containing trace amounts of phenol at 110°C for 20 h.
conjugation of haptens with bovine thyroglobulin
Human AM fragments [AM (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) and AM(46-52)NH 2 ] were allowed to react with bovine thyroglobulin and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride in 0.05 mol/L sodium phosphate buffer (pH 7.5) solution for 4 h at room temperature. The resulting reaction mixtures were dialyzed against water (4 ϫ 1000 mL) at 4°C overnight. Lyophilization of the solutions yielded the conjugate of AM fragments as a white fluffy powder. The molar ratio of the hapten (total binding) to the protein in the conjugate was determined by amino acid analysis. The molar ratios of AM (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) Hybridomas were prepared by fusion of mouse myeloma cells (X63-Ag8.653) with spleen cells from the immunized mice, using 500 g/L polyethylene glycol 4000, and cloned by the limiting dilution technique. The resulting monoclonal antibodies, AdR-1 and AdC-1, recognized the ring structure and the amidated C-terminal structure of AM, respectively. These two antibodies belonged to the IgG1 subclass and were prepared from ascites by use of Protein A (Bio-Rad Laboratories).
preparation of anti-biotin antibody
Solid sodium sulfate (Na 2 SO 4 ; 0.36 g) was added to 2 mL of anti-biotin antiserum and dissolved. After standing for 10 min at room temperature, the mixture was centrifuged at 10 000g for 20 min. The precipitate was dissolved in 0.8 mL of 17.5 mmol/L sodium phosphate buffer, pH 6.3, and dialyzed against 300 mL of the above buffer. The dialyzed sample was applied to a DEAE-cellulose column (DE52, 2 mL; Whatman International Ltd.) equilibrated with the above buffer and washed with the same buffer. The pass-through fractions were pooled, and the concentration was determined.
anti-biotin antibody-coated polystyrene beads
Polystyrene beads (6.5 mm diameter; Immuno Chemical Inc.) were incubated in 50 mmol/L phosphate buffer, pH 7.1 (buffer A), containing 15 mg/L of anti-biotin antibody for 20 h at 25°C and for 3 h at 4°C. The antibody solution was then removed from the beads, which were washed three times with buffer A. The remaining protein-binding sites on the beads were blocked by incubation with buffer A containing 250 mL/L Block Ace (Dainippon Pharmaceutical Co., Ltd., ) overnight at 4°C. After aspiration, the beads were stored in buffer B (0.1 mol/L phosphate buffer, pH 6.8, containing 0.3 mol/L NaCl, 1 mmol/L EDTA, 0.2 mmol/L cystine, 1 g/L bovine serum albumin, and 1 g/L NaN 3 ) at 4°C.
biotinylation of AdR-1
IgG (AdR-1) was digested with pepsin (IgG:pepsin ratio ϭ 1 mg:0.05 mg) for 3 h at 37°C in 100 mmol/L citrate buffer (pH 4.1) containing 100 mmol/L NaCl and F(abЈ) 2 was purified on a Sephadex G-150 column (1.5 ϫ 100 cm; Amersham Pharmacia Biotech) from undigested IgG or other digested peptides. Anti-AM(46-52)NH 2 FabЈ (196.4 g, 4.27 nmol) prepared by pepsin digestion and reduction as described above from IgG (AdC-1) was incubated with 125 I-maleimido-tyramine (296 MBq, 4.27 nmol) at 25°C for 1 h. To separate the labeled FabЈ from unreacted 125 I-maleimidotyramine, the reaction mixture was gel-filtered on an Ampure SA column (Amersham Pharmacia Biotech) in 0.1 mol/L sodium phosphate buffer, pH 6.5, containing 0.15 mol/L NaCl, followed by further purification on phenyl-Sepharose CL-4B column (0.5 ϫ 3.5 cm, Amersham Pharmacia Biotech) in the above buffer. The flowthrough fractions of labeled antibody were pooled and diluted with buffer C to give a final concentration of 210 kBq/5 mL; the pooled fractions were store in 5-mL aliquots in vials.
irma for human m-AM Before being assayed, 0.5 mL of biotinylated anti-AM(12-25) FabЈ was added to 5 mL of iodinated anti-AM(46-52)NH 2 FabЈ (final concentration of biotinylated anti-AM(12-25) FabЈ and iodinated anti-AM(46-52)NH 2 FabЈ were 2 pmol/L and 2 000 000 cpm/mL, respectively). Calibrator solutions of human AM at concentrations of 0 -300 pmol/L were prepared with buffer C containing 20 g/L human serum albumin.
In the typical assay procedure, 200 L each of calibrators or plasma samples was placed in polystyrene tubes. The mixture of labeled antibodies (100 L, 200 000 cpm/ tube) and one bead were added (total volume, 300 L), and the mixture was incubated at 4°C for 20 h. After removal of the incubation mixture, the beads were washed twice with 2 mL of distilled water, and then the radioactivities were measured with a gamma counter (ARC-600, Aloka Co., Ltd.). Experiments were performed in duplicate except where noted otherwise. Human m-AM concentrations were expressed as m-AM-like immunoreactivity.
plasma samples
Blood samples were withdrawn into plastic syringes and quickly transferred to chilled tubes containing EDTA (1.5 g/L blood) and aprotinin (50 000 kIU/L blood), and then centrifuged at 1600g at 4°C for 20 min. The plasma samples thus obtained were kept frozen below Ϫ20°C until determination. Human sample acquisition was conducted in accordance with the policies and procedures of the Institutional Review Board for the use of human subjects in research at the Diagnostic Science Division, Shionogi & Co., Ltd.
characterization of am in human plasma
Plasma from the healthy subject (10 mL) was loaded onto a Sep-Pak C 18 cartridge (Millipore-Waters) equilibrated with 5 mL of saline. After the cartridge was washed with 5 mL of saline and 100 mL/L acetonitrile in 1 mL/L TFA, the adsorbed materials were eluted with 4 mL of 600 mL/L acetonitrile in 1 mL/L TFA and lyophilized. The plasma extract was dissolved in 100 mL/L acetonitrile in 1 mL/L TFA and was analyzed by a reversed-phase HPLC using a TSK ODS 120A column (4.6 ϫ 150 mm; Tosoh). Each fraction was lyophilized and dissolved with 350 L of buffer C containing 20 g/L human serum albumin, followed by measurement of the m-AM concentration by the IRMA for m-AM.
Results characterization
Characteristics of monoclonal antibodies. After the fusion step, each of three positive clones was obtained from mice immunized with AM(12-25) or AM(46-52)NH 2 peptide conjugates. AdR-1 and AdC-1 were selected for further culture and ascites production on the basis of their association constants to m-AM and their capacity to bind m-AM simultaneously. Table 1 shows the characterization of these antibodies. The association constants were 3.2 ϫ 10 11 and 7.4 ϫ 10 10 L/mol, respectively, and clearly showed that AdR-1 and AdC-1 were highly specific for the ring structure and the amidated C-terminal structure of AM, respectively.
development of irma for m-AM
We developed a two-site IRMA for human m-AM with two kinds of monoclonal antibodies. Fig. 1 shows the principle of this IRMA for human m-AM. One of the monoclonal antibodies, which was biotinylated, recognizes the ring structure and binds to the rabbit anti-biotin antibody immobilized onto polystyrene beads, and the other, which recognizes the amidated C-terminal structure, is radioiodinated by the Hinge procedure.
analytical evaluation
Calibration curve and sensitivity. Calibration curves were prepared for the standard assay system, using synthetic human AM(1-52)NH 2 as a calibrator. Fig. 2 shows a typical calibration curve of human AM, assayed ϳ1 month after the iodination of AdC-1. The lower detection limit of this IRMA, defined as the concentration at the mean Ϯ 2 SD of 10 determinations of the zero calibrator, was 0.5 pmol/L, and the working range (CV Ͻ15%) was 1-300 pmol/L.
Precision. The reproducibility of our IRMA was estimated using three plasma samples having different AM concentrations. The within and between-day CVs were 4.4 -8.2% (n ϭ 10) and 5.5-8.3% (n ϭ 12), respectively, as shown in Table 2 .
Dilution and recovery tests. The effect of dilution of the plasma samples was investigated with three samples. As shown in Fig. 3 , the calculated AM values were linear with dilution. Recoveries of exogenously added AM from plasma samples containing three different concentrations of endogenous AM were estimated. The recovery ranged from 91% to 118%, as shown in Table 3 .
Interferences and cross-reactivity. We examined the influence of bilirubin (0.41 g/L), total lipids (1.76 g/L), and hemoglobin (1 g/L). These components of human plasma had no influence on the assay under the conditions described in Materials and Methods. We also examined the cross-reactivity with peptides (fragments) derived from AM, AM-Gly, and other peptide hormones that were related to AM or similar to AM. As shown in Fig. 4 , the assay was not cross-reactive with AM-Gly. In addition, no cross-reaction was observed with partial peptide fragments of AM, such as AM(12-25), AM(30-41), AM(38-52), AM(46-52), and AM(46-52)NH 2 (Fig. 4A) . Moreover, this IRMA had no cross-reactivities with pro-AM N-terminal 20 peptide, amylin, CGRP, calcitonin, and neuropeptide Y (Fig. 4B) . The cross-reactivity with rat AM was Ͻ1.2% on a molar basis.
AM concentration in plasma.
The m-AM concentration in plasma obtained from 61 healthy volunteers was 1.18 Ϯ 0.65 pmol/L (mean Ϯ SD; Table 4 ). Table 4 (experiment 2) shows the plasma concentrations of m-AM in patients with heart failure when they were classified according to the New York Heart Association (NYHA) functional class and with chronic renal failure (CRF). The plasma m-AM concentration in the NYHA I or II groups was significantly higher than in the control group (P Ͻ0.02), and the concentration in the NYHA III or IV groups was significantly higher than in the NYHA I or II groups (P Ͻ0.001).
Similarly, the plasma concentration in the group with CRF was significantly higher than in the control group (P Ͻ0.001).
characterization of plasma am
The elution profile by reversed-phase HPLC of a plasma extract from a healthy subject is shown in Fig. 5 . One major peak emerged at an elution position identical to that of authentic human AM(1-52)NH 2 .
stability of am in edta plasma containing aprotinin
Both high and low concentrations of exogenously added AM in EDTA plasma containing aprotinin was stable at least for 2 months at Ϫ20°C (Fig. 6B) . When stored at 4°C, the AM concentration remained mostly unchanged for 24 h (Ͼ90%); however, under more prolonged storage, the AM concentration decreased gradually (Fig. 6A) . When stored at 25 or 37°C, AM was not stable and the immunoreactivity of AM decreased to ϳ40 -50% at 2 days (Fig. 6A) . Five freeze-thaw cycles had no effect on plasma AM (data not shown).
Discussion
Plasma AM, because of its low concentration, is generally measured by means of RIA after a solid-phase extraction step, which concentrates AM and removes interfering factors (7) (8) (9) (10) (11) (12) (13) (14) . Usually, diluted plasma samples are loaded onto a conditioned Sep-Pak C 18 silica cartridge and washed sequentially. After elution of the adsorbed mate- rials, the elute undergoes lyophilization. The resulting lyophilized material is dissolved in an assay buffer and measured by RIA. This procedure is not practical for routine assay in clinical laboratories. To overcome this problem, we developed a one-step two-site IRMA. We first developed two kinds of monoclonal antibodies, AdR-1 and AdC-1, using synthetic AM (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) and AM(46-52)NH 2 , both conjugated with bovine thyroglobulin as immunogens. The epitopes in the AM molecule recognized by AdR-1 and AdC-1 were the ring structure and the amidated C-terminal structure, respectively. Because of the high specificity and sensitivity of these monoclonal antibodies to AM, we were able to develop a one-step IRMA for m-AM. Our proposed IRMA is sensitive enough to directly measure m-AM in human plasma without a prior extraction step. AM has a tendency to adhere nonspecifically to surfaces, and therefore, the nonspecific binding of "I-labeled AM" is very high in RIAs. However, in this study, we used an iodinated FabЈ of AdC-1 (monoclonal antibody recognizing the C-terminal structure), and high concentration of protein and detergent in the assay, which lowered nonspecific binding (ϳ100 cpm/tube). In Fig. 2 , we showed a typical calibration curve for AM, which was assayed ϳ1 month after iodination of FabЈ. Nevertheless, at 1 pmol/L, the CV is Ͻ15%. Moreover, the recovery of AM added to human plasma and the reproducibility of the assay gave satisfactory results.
In the present study, we were able to specifically measure the concentration of biologically active AM, m-AM, in the plasma of healthy volunteers by one-step direct assay without extraction for the first time. Unexpectedly, the concentration of m-AM was lower (1.18 Ϯ 0.65 pmol/L) than any "AM" concentration measured previously by RIAs (5.05 Ϯ 0.21 pmol/L) (13) . In addition, HPLC of a plasma extract from a healthy subject showed that our IRMA was specific for m-AM. With previously reported RIA systems, m-AM and AM-Gly could not be distinguished, and therefore, the values of the AM concentration measured by these RIAs may represent the sum of m-AM and AM-Gly. Our results indicate that the m-AM concentration is very low in circulating blood, suggesting that there is much more biologically inactive AM-Gly than m-AM. This agrees with the findings of Kitamura et al. (12) that the immunoreactivity of m-AM in plasma treated with peptidylglycine ␣-amidation enzyme was approximately fourfold higher than before treatment. They concluded that the major form of AM circulating in blood was biologically inactive AM-Gly. Lewis et al. (14) recently reported that the immunoreactivity of exogenous AM added to plasma decreased up to 70% over four freeze-thaw cycles, whereas endogenous AM was stable when measured by RIA. In our study, exogenous AM was stable over five freeze-thaw cycles when measured with our IRMA. The difference between the RIA and IRMA results may have arisen because the RIA is likely to be influenced by plasma components and the recovery of AM is not complete in the extraction step.
As described above, the AM concentration in most samples from healthy subjects was ϳ1 pmol/L. At this point, the CVs for our IRMA were rather high; however, the m-AM concentrations in plasma from patients with heart failure, CRF (Table 4) , and sepsis (unpublished data) were much higher than that of the healthy subject, which probably does not pose a serious problem for the clinical study of AM. Our observations are compatible with previous reports that used competitive RIA (7-9, 11, 13) . In this study, it is most important that we could first detect plasma m-AM without extraction. However, more detailed data are needed to clarify the relationship between plasma AM and the diseases described above.
